Current status and limitations of immunotherapy for breast cancer

Surgery. 2020 Mar;167(3):628-630. doi: 10.1016/j.surg.2019.09.018. Epub 2019 Oct 14.

Authors

Yoshihisa Tokumaru¹, Daniel Joyce¹, Kazuaki Takabe²

Affiliations

¹ Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
² Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York, NY. Electronic address: Kazuaki.Takabe@roswellpark.org.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast / immunology
Breast / pathology
Breast / surgery
Breast Neoplasms / immunology
Breast Neoplasms / mortality
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Chemoradiotherapy, Adjuvant / methods
Clinical Decision-Making
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
Costimulatory and Inhibitory T-Cell Receptors / immunology
Costimulatory and Inhibitory T-Cell Receptors / metabolism
Female
Humans
Immunotherapy / methods*
Mastectomy
Neoplasm Recurrence, Local / epidemiology*
Neoplasm Recurrence, Local / immunology
Neoplasm Recurrence, Local / pathology
Patient Selection
Prognosis
Randomized Controlled Trials as Topic
Survival Rate
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Costimulatory and Inhibitory T-Cell Receptors

Grants and funding